In Brief
Two Ways to Solve One Problem
In transthyretin amyloidosis the transport protein transthyretin loses stability, falls apart, and the loose parts clump into amyloid fibrils that deposit in the heart and nerves.
There are exactly two ways to intervene.
The second is not to produce the protein at all. No protein, nothing to fall apart. That is vutrisiran's route.
| Stabilisers (tafamidis, acoramidis) | Vutrisiran | |
|---|---|---|
| What they do | Hold existing protein together | Prevent it being made |
| Where they act | In the blood | In liver cells |
| Form | Daily tablets | Injection every 3 months |
| Reduction in transthyretin level | Minimal | About 80% |
| Removes amyloid already deposited | No | No |
How a Gene Is Silenced
A gene is a blueprint. To build a protein from it, the cell first makes a working copy — messenger RNA — and assembly runs off that copy.
A small interfering RNA is a short fragment that recognises a specific copy and marks it for destruction. The blueprint stays untouched, but the working copies never reach the assembly floor, and the protein is not made.
The mechanism was not invented: cells use RNA interference to defend against viruses. Medicine merely learned to aim it at a chosen gene.
Delivery was a separate engineering problem. A carbohydrate address, GalNAc, is attached to the molecule, and liver cells actively take up anything carrying it. Transthyretin is produced chiefly by the liver, so the targeting lands precisely on target — and makes one injection every three months enough.
What the Cardiac Trial Showed
▸HELIOS-B (NEJM, 2025) — 655 patients with transthyretin amyloid cardiomyopathy [1].
| Measure | Result |
|---|---|
| Death from any cause + recurrent cardiovascular events | Hazard ratio *0.72* (95% CI 0.56–0.93; p=0.01) |
| Death from any cause through 42 months | Hazard ratio *0.65* (95% CI 0.46–0.90; p=0.01) |
| Six-minute walk test | *26.5 m* difference favouring the drug (p<0.001) |
| Quality of life (KCCQ) | *5.8 point* difference (p<0.001) |
| Adverse events | 99% versus 98% on placebo |
| Serious events | 62% versus 67% |
The second row is the key one. A 35% reduction in death from any cause means the drug affects not only measurements and wellbeing but how long a person lives. In chronic-disease trials that difference is far from routinely achieved.
One more practically important detail: about 40% of participants were already taking tafamidis, and adding vutrisiran benefited them too. The question of layering on top of a stabiliser was tested inside the trial rather than reasoned out afterwards.
▸HELIOS-A (Amyloid, 2023) — the trial in the hereditary form with polyneuropathy, on which the drug's first indication rests [2].
About Vitamin A
Transthyretin carries thyroid hormone and vitamin A. When its level falls by 80%, vitamin A transport suffers.
Thyroid hormones are not noticeably affected: thyroxine has other carriers. But vitamin A levels genuinely drop, so patients on drugs of this class are prescribed vitamin A at a dose their doctor specifies, and complaints related to night vision are given particular attention.
What Cannot Be Claimed Yet
▸That it is better than stabilisers — no head-to-head trial of vutrisiran against tafamidis or acoramidis has been run. ▸That it dissolves deposited amyloid: it cuts off the supply of new material, nothing more. ▸That combining with a stabiliser is right for everyone — data on combined use exist, but that is not a general rule. ▸What the consequences of an 80% reduction in transthyretin over many years are — observation so far is measured in years, not decades.
Who It Is Not For
▸Patients with light-chain amyloidosis: a different disease with different treatment. ▸Anyone without a confirmed diagnosis — treatment begins after scintigraphy or genetic confirmation, not on suspicion. ▸As a replacement for baseline heart failure therapy. ▸Anyone unwilling to attend regular follow-up: monitoring vitamin A and cardiac status is part of the treatment.
Bottom Line
▸A different level of intervention: not holding the protein together but preventing its production — about an 80% reduction in transthyretin. ▸An effect on survival is demonstrated: 35% lower death from any cause through 42 months. ▸Convenience: a subcutaneous injection every three months instead of daily tablets. ▸Compatibility with a stabiliser was tested inside the trial in 40% of participants. ▸The shared limitation of the class: amyloid already deposited is not removed, so early diagnosis decides the outcome.
Treatment can be discussed at a consultation; the drug can be ordered here.
References
1. Fontana M, et al. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2025;392(1):33–44. PMID 39213194
2. Adams D, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):1–9. PMID 35875890
3. Gillmore JD, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2024;390(2):132–142. PMID 38197816
4. AMVUTTRA (vutrisiran) — US Prescribing Information, Alnylam Pharmaceuticals.
Key facts
- Vutrisiran (brand name Amvuttra, Alnylam) is a small interfering RNA therapeutic that suppresses production of transthyretin in the liver.
- The FDA approved it in June 2022 for polyneuropathy in hereditary transthyretin amyloidosis, and in March 2025 extended the indication to amyloid cardiomyopathy.
- It is given subcutaneously once every three months — four injections a year, with no infusions and no hospital visit.
- The principle is the opposite of a stabiliser: those hold the protein together, while vutrisiran prevents it being made, lowering transthyretin levels by roughly 80%.
- HELIOS-B (NEJM, 2025): 655 patients; the risk of death from any cause together with recurrent cardiovascular events fell by 28% (hazard ratio 0.72; 95% CI 0.56–0.93; p=0.01).
- Death from any cause through 42 months fell by 35% (hazard ratio 0.65; 95% CI 0.46–0.90; p=0.01) — an effect on survival, not merely on how patients feel.
- Function was better preserved: the difference on the six-minute walk test was 26.5 m and on the KCCQ quality-of-life score 5.8 points (both p<0.001).
- About 40% of participants were already taking tafamidis, and the benefit of adding vutrisiran held for them — the question of layering on top of a stabiliser was answered inside the trial.
- Tolerability: adverse events 99% versus 98% on placebo, serious ones 62% versus 67%, so the drug added no risk.
- The limit of the approach: it does not remove amyloid already deposited and does not act on transthyretin already in the tissues — it only cuts off the supply of new material.
